Pretty likely vass, Managent seems to present an "alternative" business plan every other month. Like non-toxic to triple therapy, CEO changes, CFO changes, pipeline, studies shelved etc.
I’ll just simply comment with hopefully more to come but we are having increased interest in geographic rights for Zoptrex as we approach the timing of completion of the trial and discussions, negotiations are under way in that regard for other geographic areas as well as additional increase still coming in that we would like to meet with. And we have really ramped up in this regard on that product.
On Q1 conference call Dodd said they are in discussions on partnerships with interested parties and additional parties have now made interest as well. This week we see Dodd step down as Chair and Egbert take over for "corporate compliance" reasons. What does this tell us? Answer, we are about to cut a deal and they want the decision making of the Board to be independent of Management ... stay tuned
I think the early speculators are starting to arrive, should continue a nice uptrend right to end of year ...